196 related articles for article (PubMed ID: 18499705)
1. Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative.
Barch DM; Carter CS;
Schizophr Bull; 2008 Jul; 34(4):613-8. PubMed ID: 18499705
[TBL] [Abstract][Full Text] [Related]
2. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.
Carter CS; Barch DM; Buchanan RW; Bullmore E; Krystal JH; Cohen J; Geyer M; Green M; Nuechterlein KH; Robbins T; Silverstein S; Smith EE; Strauss M; Wykes T; Heinssen R
Biol Psychiatry; 2008 Jul; 64(1):4-10. PubMed ID: 18466880
[TBL] [Abstract][Full Text] [Related]
3. Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.
Keefe RS; Harvey PD
Schizophr Bull; 2008 Jul; 34(4):656-63. PubMed ID: 18495645
[TBL] [Abstract][Full Text] [Related]
4. Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting.
Barch DM; Carter CS; Arnsten A; Buchanan RW; Cohen JD; Geyer M; Green MF; Krystal JH; Nuechterlein K; Robbins T; Silverstein S; Smith EE; Strauss M; Wykes T; Heinssen R
Schizophr Bull; 2009 Jan; 35(1):109-14. PubMed ID: 19023126
[TBL] [Abstract][Full Text] [Related]
5. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
[TBL] [Abstract][Full Text] [Related]
6. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
Green MF; Nuechterlein KH; Kern RS; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Seidman LJ; Stover E; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):221-8. PubMed ID: 18172017
[TBL] [Abstract][Full Text] [Related]
7. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.
Carter CS; Barch DM
Schizophr Bull; 2007 Sep; 33(5):1131-7. PubMed ID: 17630405
[TBL] [Abstract][Full Text] [Related]
8. Measuring specific, rather than generalized, cognitive deficits and maximizing between-group effect size in studies of cognition and cognitive change.
Silverstein SM
Schizophr Bull; 2008 Jul; 34(4):645-55. PubMed ID: 18468987
[TBL] [Abstract][Full Text] [Related]
9. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.
Kern RS; Nuechterlein KH; Green MF; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Mintz J; Seidman LJ; Stover E; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):214-20. PubMed ID: 18172018
[TBL] [Abstract][Full Text] [Related]
10. The translation of cognitive paradigms for patient research.
Luck SJ; Gold JM
Schizophr Bull; 2008 Jul; 34(4):629-44. PubMed ID: 18487226
[TBL] [Abstract][Full Text] [Related]
11. Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders.
Carter CS; Barch DM; Bullmore E; Breiling J; Buchanan RW; Butler P; Cohen JD; Geyer M; Gollub R; Green MF; Jaeger J; Krystal JH; Moore H; Nuechterlein K; Robbins T; Silverstein S; Smith EE; Strauss M; Wykes T
Biol Psychiatry; 2011 Jul; 70(1):7-12. PubMed ID: 21529781
[TBL] [Abstract][Full Text] [Related]
12. Building a clinically relevant cognitive task: case study of the AX paradigm.
MacDonald AW
Schizophr Bull; 2008 Jul; 34(4):619-28. PubMed ID: 18487225
[TBL] [Abstract][Full Text] [Related]
13. Adapting social neuroscience measures for schizophrenia clinical trials, Part 2: trolling the depths of psychometric properties.
Kern RS; Penn DL; Lee J; Horan WP; Reise SP; Ochsner KN; Marder SR; Green MF
Schizophr Bull; 2013 Nov; 39(6):1201-10. PubMed ID: 24072805
[TBL] [Abstract][Full Text] [Related]
14. Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models.
Moore H; Geyer MA; Carter CS; Barch DM
Neurosci Biobehav Rev; 2013 Nov; 37(9 Pt B):2087-91. PubMed ID: 24090823
[TBL] [Abstract][Full Text] [Related]
15. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
Green MF; Nuechterlein KH; Gold JM; Barch DM; Cohen J; Essock S; Fenton WS; Frese F; Goldberg TE; Heaton RK; Keefe RS; Kern RS; Kraemer H; Stover E; Weinberger DR; Zalcman S; Marder SR
Biol Psychiatry; 2004 Sep; 56(5):301-7. PubMed ID: 15336511
[TBL] [Abstract][Full Text] [Related]
16. The cognitive neuroscience of working memory: relevance to CNTRICS and schizophrenia.
Barch DM; Smith E
Biol Psychiatry; 2008 Jul; 64(1):11-7. PubMed ID: 18400207
[TBL] [Abstract][Full Text] [Related]
17. Food and Drug Administration commentary on methodological issues in negative symptom trials.
Laughren T; Levin R
Schizophr Bull; 2011 Mar; 37(2):255-6. PubMed ID: 21245124
[No Abstract] [Full Text] [Related]
18. The MATRICS consensus cognitive battery: what we know 6 years later.
Green MF; Harris JG; Nuechterlein KH
Am J Psychiatry; 2014 Nov; 171(11):1151-4. PubMed ID: 25756630
[No Abstract] [Full Text] [Related]
19. Executive functioning component mechanisms and schizophrenia.
Kerns JG; Nuechterlein KH; Braver TS; Barch DM
Biol Psychiatry; 2008 Jul; 64(1):26-33. PubMed ID: 18549874
[TBL] [Abstract][Full Text] [Related]
20. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
Buchanan RW
Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932
[No Abstract] [Full Text] [Related]
[Next] [New Search]
